描述

An autoimmune disease is a condition arising from an abnormal immune response to a functioning body part. There are around 80 different autoimmune disorders ranging in severity from mild to disabling, depending on which system of the body is under attack and to what degree. The global autoimmune disease diagnostics market is set to grow by US$ 2 亿期间 2021-2027, 以复合年增长率增长 (复合年增长率) 的 5.1% 在预测期内, 据数据和分析公司 StrategyHelix 称. Growing patient awareness levels concerning autoimmune diseases, presence of favorable government initiatives, improved laboratory automation, rise in the geriatric population and growing prevalence of obesity, 类型 1 diabetes and other chronic diseases are expected to boost the market growth in the coming years.

该报告提供了该时期的最新市场规模数据 2017-2020 并预测到 2027 covering key market aspects like sales value for autoimmune disease diagnostics. The global autoimmune disease diagnostics market is segmented on the basis of type, 性别, 技术, 和地区. 按类型, it is categorized into systemic autoimmune disease diagnostics, and localized autoimmune disease diagnostics. The localized autoimmune disease diagnostics segment held the largest market share in 2020. 按性别, the autoimmune disease diagnostics market is divided into female, and male. The female segment accounted for the largest market share in 2020. Based on technology, the autoimmune disease diagnostics market is divided into enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence (IIF), immunoblot, multiplex immunoassays, 和别的.

The systemic autoimmune disease diagnostics market is further segmented into rheumatoid arthritis, psoriasis/psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis, 和别的. 他们之中, rheumatoid arthritis segment held the largest market share in 2020. The localized autoimmune disease diagnostics market is further segmented into inflammatory bowel disease, 类型 1 糖尿病, thyroid, 和别的. 在这些当中, thyroid segment held the largest market share in 2020.

The report has profiled some of the key players of the market such as Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), Becton Dickinson and Company, bioMerieux Inc., Bio-Rad AbD Serotec Limited, Bristol Myers Squibb (BMS), EUROIMMUN AG (PerkinElmer Inc.), F. Hoffmann-La Roche AG, Immuno Concepts Inc., INOVA Diagnostics Inc., Siemens Healthineers AG, SQI Diagnostics Inc., Thermo Fisher Scientific Inc., Trinity Biotech plc (IMMCO Diagnostics Inc).

该报告对于活跃在该行业的公司和组织来说是宝贵的资源. It provides a cohesive picture of the autoimmune disease diagnostics market to help drive informed decision making for industry executives, 政策制定者, 学术的, 和分析师.

报告范围

类型: systemic autoimmune disease diagnostics, and localized autoimmune disease diagnostics
性别: female, and male
技术: enzyme-linked immunosorbent assay (ELISA), indirect immunofluorescence (IIF), immunoblot, multiplex immunoassays, 和别的
地区: 北美, 亚太地区, 欧洲, 和世界其他地区 (排)
考虑年数: 本报告涵盖期间 2017 到 2027

利益相关者的主要好处

Get a comprehensive picture of the global autoimmune disease diagnostics market
根据当地数据和分析确定区域战略和战略重点
精准定位增长领域和投资趋势
Understand what the future of the global autoimmune disease diagnostics market looks like
确定竞争格局和机会之窗

目录

1. 市场定义
2. 研究方法论
3. 市场数据 & 外表
3.1 市场价值
3.2 市场价值预测
4. Autoimmune Disease Diagnostics Market by Type
4.1 Systemic Autoimmune Disease Diagnostics
4.2 Localized Autoimmune Disease Diagnostics
5. Autoimmune Disease Diagnostics Market by Gender
5.1 女性
5.2 男性
6. Autoimmune Disease Diagnostics Market by Technology
6.1 Enzyme-Linked Immunosorbent Assay (Elisa)
6.2 Indirect Immunofluorescence (Iif)
6.3 Immunoblot
6.4 Multiplex Immunoassays
6.5 其他的
7. Autoimmune Disease Diagnostics Market by Region
7.1 北美
7.2 亚太地区
7.3 欧洲
7.4 世界其他地区 (排)
8. 公司简介
8.1 雅培实验室
8.2 Beckman Coulter Inc. (Danaher Corporation)
8.3 Becton, Dickinson and Company
8.4 bioMerieux, 公司.
8.5 Bio-Rad AbD Serotec Limited
8.6 Bristol Myers Squibb (BMS)
8.7 EUROIMMUN AG (PerkinElmer, 公司)
8.8 F. Hoffmann-La Roche AG
8.9 Immuno Concepts, 公司.
8.10 INOVA Diagnostics, 公司.
8.11 Siemens Healthineers AG
8.12 SQI Diagnostics, 公司.
8.13 Thermo Fisher Scientific Inc.
8.14 Trinity Biotech plc (IMMCO Diagnostics Inc)
9. 附录
9.1 关于StrategyHelix
9.2 免责声明